|
Synonyms: NutropinAq® | Omnitrope® | Saizen® | somatotropin
growth hormone 1 is an approved drug (FDA (1976), EMA (2001))
Compound class:
Endogenous peptide in human, mouse or rat
Comment: Human growth hormone 1 (somatropin) produced by recombinant technology is an approved drug with the INN somatropin. This has identical 191-amino acid sequence to the endogenous hormone.
Biosimilar drug: The EMA approved the biosimilar named Omnitrope (Sandoz GmbH) in 2006.
Species: Human
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖
View more information in the IUPHAR Pharmacology Education Project: growth hormone 1 |
| No information available. |
Summary of Clinical Use  |
| Somatropin is used to treat growth failure caused by a lack natural growth hormone (e.g. arising from chronic kidney failure, Noonan syndrome, Turner syndrome, Prader-Willi syndrome or achondroplasia) and can also be used for the prevention of HIV-induced weight loss. The 2001 EMA approval indicates the use of somatropin to treat Turner syndrome. |
| Mechanism Of Action and Pharmacodynamic Effects |
| For an overview of the mechanism of action of somatropin, please see the entry on DrugBank linked to from this ligand page. |
| External links |
|
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |
